InsiderSource

ROSENWALD LINDSAY A MD

Director, PRESIDENT, CEO & CHAIRMAN, 10% Owner, President, CEO & Chairman · SEC CIK 941841
Insider at FBIO Fortress Biotech, Inc. DERM Journey Medical Corp CKPT Checkpoint Therapeutics, Inc. ATXI AVENUE THERAPEUTICS, INC. MBIO MUSTANG BIO, INC.
Advertisement

Buy track record

How this insider's open-market purchases have performed
52%
of buys now in profit
11 up · 10 down
Avg return since buy+5.7%
Median return+14.5%
Best trade+152.6%
Worst trade−99.9%
Buys scored21
Average return by holding period — separates good entry timing from riding one long winner
After 1 month +4.6% 48% won · 21 trades
After 3 months +2.0% 43% won · 21 trades
After 6 months −7.0% 43% won · 21 trades
After 12 months −11.8% 43% won · 21 trades
DateCompany90d trendBuy priceValueΔOwn1M3M6M12MTo date
Sep 23, 2024 FBIO $2 $1.4M +26% +24.5% +21.7% +20.3% +155.2% +93.7%
Jul 11, 2024 FBIO $7 $37.4K +4.1% −10.2% −17.3% +0.0% −4.1% +40.6%
Jul 9, 2024 FBIO $7 $37K +4.3% +6.4% −8.1% +18.0% +15.7% +61.0%
Jul 8, 2024 FBIO $7 $36.8K +4.4% +6.9% −12.6% +18.9% +10.3% +58.3%
Jun 28, 2024 FBIO $2 $32.7K +0.7% +28.7% −15.2% +27.5% +8.8% +62.0%
May 16, 2024 FBIO $2 $17.6K +0.3% +8.0% +5.7% −15.9% +2.8% +57.4%
Mar 25, 2024 DERM $3 $30.4K +7.4% +19.9% +70.5% +85.6% +121.9% +117.1%
Mar 22, 2024 DERM $3 $68K +18% +7.3% +49.4% +56.4% +98.2% +92.1%
Jan 5, 2024 FBIO $2 $118.8K +1.8% −28.9% −22.7% −25.6% −6.6% +14.5%
Nov 14, 2023 FBIO $2 $2.66M +152% +150.8% +42.4% +33.3% +18.9% +109.8%
Sep 26, 2023 FBIO $0 $28.3K +0.7% −57.1% −20.2% −54.0% −65.5% −34.0%
Sep 8, 2023 ATXI $1 $251K +999% −16.0% −79.5% −74.4% −94.6% −99.4%
Sep 6, 2023 DERM $2 $223K +702% +15.1% +142.6% +39.0% +86.5% +152.6%
Aug 18, 2023 FBIO $9 $93.4K +9.8% −20.5% −57.6% −73.0% −70.6% −58.0%
Aug 17, 2023 FBIO $12 $117.5K +11% −14.6% −66.0% −71.1% −68.5% −55.0%
Feb 10, 2023 FBIO $1 $2M +18% −5.3% −2.6% −30.3% −83.2% −75.7%
Dec 1, 2022 FBIO $1 $68K +0.9% −1.5% +13.6% −16.7% −78.1% −72.0%
Nov 30, 2022 FBIO $1 $2.8K — +0.0% +13.6% −18.2% −80.0% −72.0%
Oct 21, 2022 FBIO $1 $69.5K +0.9% +13.2% +45.6% +4.4% −82.9% −72.8%
Sep 13, 2022 MBIO $1 $2.6K +1.7% −18.8% −28.8% −30.7% −70.6% −99.8%
Mar 18, 2022 MBIO $1 $3K +1.9% −12.2% −32.7% −40.6% −62.0% −99.9%
How this is calculated. We score only open-market purchases (SEC code P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 21 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$7.31M
21 trades
Open-market sells
$0
0 trades
Net flow
+$7.31M
Net buying
Total filings
50
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
Advertisement
FBIO
Fortress Biotech, Inc.
Buy ROSENWALD LINDSAY A MD · Director, PRESIDENT, CEO & CHAIRMAN, 10% Owner · Open-market purchase · filed Sep 25, 2024 ΔOwn +26%

Rosenwald Lindsay A Md, FBIO's CEO, spent $1.4M of their own money on 763,359 shares at $2, growing their stake 26%.

+$1.4M
763,359 sh @ $2
FBIO
Fortress Biotech, Inc.
Buy ROSENWALD LINDSAY A MD · Director, President, CEO & Chairman, 10% Owner · Open-market purchase · filed Jul 15, 2024 ΔOwn +4.1%

Rosenwald Lindsay A Md, FBIO's CEO, spent $37.4K of their own money on 5,000 shares at $7, growing their stake 4%.

+$37.4K
5,000 sh @ $7
FBIO
Fortress Biotech, Inc.
Buy ROSENWALD LINDSAY A MD · Director, President, CEO & Chairman, 10% Owner · Open-market purchase · filed Jul 11, 2024 ΔOwn +4.3%

Rosenwald Lindsay A Md, FBIO's CEO, spent $37K of their own money on 5,000 shares at $7, growing their stake 4%.

+$37K
5,000 sh @ $7
FBIO
Fortress Biotech, Inc.
Buy ROSENWALD LINDSAY A MD · Director, President, CEO & Chairman, 10% Owner · Open-market purchase · filed Jul 10, 2024 ΔOwn +4.4%

Rosenwald Lindsay A Md, FBIO's CEO, spent $36.8K of their own money on 5,000 shares at $7, growing their stake 4%.

+$36.8K
5,000 sh @ $7
FBIO
Fortress Biotech, Inc.
Buy ROSENWALD LINDSAY A MD · Director, President, CEO & Chairman, 10% Owner · Open-market purchase · filed Jul 1, 2024 ΔOwn +0.7%

Rosenwald Lindsay A Md, FBIO's CEO, spent $32.7K of their own money on 20,000 shares at $2, growing their stake 1%.

+$32.7K
20,000 sh @ $2
FBIO
Fortress Biotech, Inc.
Buy ROSENWALD LINDSAY A MD · Director, President, CEO & Chairman, 10% Owner · Open-market purchase · filed May 20, 2024 ΔOwn +0.3%

Rosenwald Lindsay A Md, FBIO's CEO, spent $17.6K of their own money on 10,000 shares at $2.

+$17.6K
10,000 sh @ $2
DERM
Journey Medical Corp
Buy ROSENWALD LINDSAY A MD · Director · Open-market purchase · filed Mar 27, 2024 ΔOwn +7.4%

Rosenwald Lindsay A Md, DERM's Director, spent $30.4K of their own money on 10,000 shares at $3, growing their stake 7%.

+$30.4K
10,000 sh @ $3
DERM
Journey Medical Corp
Buy ROSENWALD LINDSAY A MD · Director · Open-market purchase · filed Mar 25, 2024 ΔOwn +18%

Rosenwald Lindsay A Md, DERM's Director, spent $68K of their own money on 20,000 shares at $3, growing their stake 18%.

+$68K
20,000 sh @ $3
FBIO
Fortress Biotech, Inc.
Buy ROSENWALD LINDSAY A MD · Director, President, CEO & Chairman, 10% Owner · Open-market purchase · filed Jan 9, 2024 ΔOwn +1.8%

Rosenwald Lindsay A Md, FBIO's CEO, spent $118.8K of their own money on 50,000 shares at $2, growing their stake 2%.

+$118.8K
50,000 sh @ $2
FBIO
Fortress Biotech, Inc.
Buy ROSENWALD LINDSAY A MD · Director, President, CEO & Chairman, 10% Owner · Open-market purchase · filed Nov 16, 2023 ΔOwn +152%

Rosenwald Lindsay A Md, FBIO's CEO, spent $2.66M of their own money on 1.57M shares at $2, growing their stake 152%.

+$2.66M
1.57M sh @ $2
FBIO
Fortress Biotech, Inc.
Buy ROSENWALD LINDSAY A MD · Director, President, CEO & Chairman, 10% Owner · Open-market purchase · filed Sep 27, 2023 ΔOwn +0.7%

Rosenwald Lindsay A Md, FBIO's CEO, spent $28.3K of their own money on 100,000 shares at $0, growing their stake 1%.

+$28.3K
100,000 sh @ $0
ATXI
AVENUE THERAPEUTICS, INC.
Buy ROSENWALD LINDSAY A MD · Director · Open-market purchase · filed Sep 12, 2023 ΔOwn +999%

Rosenwald Lindsay A Md, ATXI's Director, spent $251K of their own money on 348,675 shares at $1, growing their stake 6179%.

+$251K
348,675 sh @ $1
DERM
Journey Medical Corp
Buy ROSENWALD LINDSAY A MD · Director · Open-market purchase · filed Sep 8, 2023 ΔOwn +702%

Rosenwald Lindsay A Md, DERM's Director, spent $223K of their own money on 100,000 shares at $2, growing their stake 702%.

+$223K
100,000 sh @ $2
FBIO
Fortress Biotech, Inc.
Buy ROSENWALD LINDSAY A MD · Director, President, CEO & Chairman, 10% Owner · Open-market purchase · filed Aug 21, 2023 ΔOwn +9.8%

Rosenwald Lindsay A Md, FBIO's CEO, spent $93.4K of their own money on 10,000 shares at $9, growing their stake 10%.

+$93.4K
10,000 sh @ $9
FBIO
Fortress Biotech, Inc.
Buy ROSENWALD LINDSAY A MD · Director, President, CEO & Chairman, 10% Owner · Open-market purchase · filed Aug 21, 2023 ΔOwn +11%

Rosenwald Lindsay A Md, FBIO's CEO, spent $117.5K of their own money on 10,000 shares at $12, growing their stake 11%.

+$117.5K
10,000 sh @ $12
FBIO
Fortress Biotech, Inc.
Buy ROSENWALD LINDSAY A MD · Director, President, CEO & Chairman, 10% Owner · Open-market purchase · filed Feb 14, 2023 ΔOwn +18%

Rosenwald Lindsay A Md, FBIO's CEO, spent $2M of their own money on 2.4M shares at $1, growing their stake 18%.

+$2M
2.4M sh @ $1

Frequently asked questions

How is ROSENWALD LINDSAY A MD's win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from ROSENWALD LINDSAY A MD's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.